Difference in angiotensinogen haplotype frequences between chronic heart failure and advanced atherosclerosis patients - new prognostic factor?
|Druh||Článek v odborném periodiku|
|Časopis / Zdroj||Physiological Research|
|Fakulta / Pracoviště MU|
|Obor||Genetika a molekulární biologie|
|Klíčová slova||RAAS; heart failure; AGT|
|Popis||Numerous association studies have been involved in studying the angiotensinogen (AGT) variants, AGT plasma levels and relations to cardiovascular diseases, such as hypertension, myocardial infarction, coronary heart disease. To investigate a role of AGT G(-6)A and M235T genetic variants for chronic heart failure (CHF) and advanced atherosclerosis (AA), a total of 240 patients with CHF and 200 patients with AA of the Czech origin were evaluated for the study. The study shows the role of polymorphism AGT G(-6)A in genetic background among advanced atherosclerosis patients and chronic heart failure patients (Pg=0.001). This difference was observed also in comparison of AA patients with subgroup of CHF with dilated cardiomyopathy (Pg=0.02; Pa=0.009), and ischemic heart disease (Pg=0.007). The greatest difference between triple-vessel disease and chronic heart failure groups was observed in frequency of GT haplotype (P<0.001) and GGMT associated genotype (P<0.001). Retrospectively, when the subgroups of CHF were compared to AA group (AA vs. IHD with CHF - P < 0.001; and AA vs. DCM - P<0.001) we found the same trend. These results suggest AGT genetic variants as a risk factor for chronic heart failure compared to advanced atherosclerosis disease without heart failure, with a strong difference between IHD patients and chronic heart failure patients with ischemic heart disease, especially in haplotypes and associated genotypes.|